Heart failure drug may boost red blood cells and organ health
NCT ID NCT07478575
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines whether SGLT2 inhibitors, a type of diabetes drug, can improve red blood cell production and heart/kidney function in people with chronic heart failure. Researchers will compare blood tests, heart ultrasound measures, and clinical outcomes between 85 patients who started the drug and a matched group who did not, over 12 months. The goal is to understand how these drugs might help beyond blood sugar control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less be more? testing transfusion limits in ECMO
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?